GSK (GSK) reaches agreement to acquire Bellus Health (BLU). George Tsilis joins Alex Coffey and Jenny Horne to discuss this as the deal is worth approximately $2B or $14.75 per share. He talks about how the deal is expected to close in 3Q23 or earlier. BLU is a late-stage biopharma company whose experimental cough medicine "Camlipixant" is expected to launch in 2026. Tune in to find out more about the stock market today.
18 Apr 2023
Market On Close
28 Mar 2023
Market On Close
03 May 2023
The Watch List
17 May 2023
Market On Close
16 May 2023
Market On Close
23 May 2023
Trading 360
04 May 2023